Press Releases
Ventripoint Announces $2,000,000 Non-Brokered Private Placement and Cross TradeToronto, Ontario, August 16, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or
the “Corporation”, TSXV:VPT, OTCQB:VPTDF) announces that it intends to complete a non-brokered private placement (the “Private Placement”) of up to 13,333,333 units of the Corporation (“Units”) at CDN$0.15 per Unit for total gross proceeds of up to CDN$2,000,000 (the “Offering”). Each Unit will be comprised of: (i) one common share of the Corporation (“Common Share”); and (ii) one common share purchase warrant (“Warrant”) with each Warrant exercisable for one Common Share at an exercise price of CDN$0.175 per Common Share for a period of 36 months after the issuance of the Warrant. Depending on market conditions, the Corporation reserves the right to increase the maximum gross proceeds under the Offering, subject to approval of the TSX Venture Exchange (the “Exchange”). Read More... Ventripoint Commends Mazankowski Alberta Heart Institute on their Feasibility Study Finding the VMS+ System Can Obviate the Need for Contrast Agents for LV Volumes and EFToronto, Ontario, August 06, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that Dr. Windram and his group of researchers at the Mazankowski Alberta Heart Institute in Edmonton have completed a clinical study on the ability of the VMS+ whole-heart analysis system to analyze 2D echocardiograms of left-ventricle (LV) volumes and ejection fractions (LVEF) without the need for intravenous ultrasonographic enhancing agents. This feasibility study concluded: “The use of the Ventripoint knowledge-based-reconstruction technique revealed no significant differences in the measurement of left ventricular volumes or ejection fraction in comparison with contrast echocardiography measurements.” Read More...
Ventripoint Manufacturing Facility Passed Inspection and First Two VMS+ 3.0 Heart Analysis Machines Shipping to Western CanadaToronto, Ontario, July 31, 2019 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”,
TSXV:VPT, OTCQB:VPTDF) is pleased to announce that its manufacturing facility for the VMS+ 3.0 whole heart analysis system received its initial inspection and passed on July 25th, 2019. The first two devices are being fabricated and are on schedule to ship this week to fulfill purchase orders at a Heart Institute and a Children’s Hospital in Western Canada (see Ventripoint News Releases from July 15th & 16th, 2019). Read More... A Second Canadian Heart Institute to Receive Ventripoint
|
For further information please contact:
Dr. George Adams, CEO
Phone: (519) 803-6937
Email: gadams@ventripoint.com
|
